CombiGene’s CEO Jan Nilsson describes how the collaboration and licensing agreement with Spark Therapeutics creates new business development opportunities at Stora Aktiedagen Stockholm November 30, at 16.30

News 2021 2021   2020   2019   2018   2017   2016   2015   The agreement provides Spark with the exclusive world-wide license to develop, manufacture and commercialize CG01. Under the terms of agreement, CombiGene is eligible to receive up to $328.5 million...

read more

The EU continues to invest in CombiGene

2021   2020   2019   2018   2017   2016   2015   This is an article from Ingeneious number 2 2021.Read the whole Ingeneious here >> CombiGene’s epilepsy project CG01 has already been granted EUR 3.36 million by the EU programme Horizon 2020. Now the EU is...

read more

Gunilla Lundmark new board member of CombiGene

News 2021 2021   2020   2019   2018   2017   2016   2015 At CombiGene’s Annual General Meeting, Gunilla Lundmark was elected as new member of the Board of Directors. Gunilla is an entrepreneur through and through, and has 25 years of experience from leading positions...

read more

First in human study within reach

News 2021 2021   2020   2019   2018   2017   2016   2015   This is an article from Ingeneious number 2 2021.Read the whole Ingeneious here >> A lot has happened at CombiGene during the first months of 2021 and when Ingeneious gets the opportunity to talk to...

read more

CombiGene annual report 2020

Financial reports 2021 2021   2020   2019   2018   2017   2016   2015   2014   2013 Annual report 2020>> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene...

read more

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

 

CombiGene AB, Agavägen 52A, SE-181 55 Lidingö

 

Linked In     Twitter      Facebook